Literature DB >> 33548625

Discovery of selective BPTF bromodomain inhibitors by screening and structure-based optimization.

Liang Xiong1, Xin Mao1, Yinping Guo1, Yangli Zhou1, Mingxin Chen1, Pei Chen2, Shengyong Yang1, Linli Li3.   

Abstract

Bromodomain and PHD finger containing transcription factor (BPTF) is a multidomain protein that regulates the transcription of chromatin and is related to many cancers. Herein, we report the screening-based discovery of Cpd1, a compound with micromolar affinity to the BPTF bromodomain. Through structure-guided optimization, we synthesized a variety of new inhibitors. Among these compounds, Cpd8 and Cpd10 were highly potent and selective inhibitors, with KD values of 428 nM and 655 nM in ITC assays, respectively. The high activity was explained by the cocrystal structure of Cpd8 in complex with the BPTF bromodomain protein. Cpd8 and Cpd10 were able to stabilize the BPTF bromodomain protein in cells in a cellular thermal shift assay (CETSA). Cpd8 downregulated c-MYC expression in A549 cells. All experiments prove that these two compounds are potential BPTF inhibitors.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BPTF; Bromodomain; Epigenetics; Inhibitors; Structure-based optimization

Year:  2021        PMID: 33548625     DOI: 10.1016/j.bbrc.2021.01.067

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  New Design Rules for Developing Potent Cell-Active Inhibitors of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition.

Authors:  Huda Zahid; Caroline R Buchholz; Manjulata Singh; Michael F Ciccone; Alice Chan; Stanley Nithianantham; Ke Shi; Hideki Aihara; Marcus Fischer; Ernst Schönbrunn; Camila O Dos Santos; Joseph W Landry; William C K Pomerantz
Journal:  J Med Chem       Date:  2021-09-13       Impact factor: 8.039

2.  Targeting BPTF Sensitizes Pancreatic Ductal Adenocarcinoma to Chemotherapy by Repressing ABC-Transporters and Impairing Multidrug Resistance (MDR).

Authors:  Raúl Muñoz Velasco; Paula Jiménez Sánchez; Ana García García; Raquel Blanco Martinez-Illescas; Ángela Pastor Senovilla; Marian Lozano Yagüe; Alfonsina Trento; Rosa María García-Martin; Diego Navarro; Bruno Sainz; José Luis Rodríguez Peralto; Víctor Javier Sánchez-Arévalo Lobo
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.